To List Or Not To List; That Is The Question – The FTC Signals The Potential For Greater Scrutiny Of Patent Information Submissions To FDA - Food and Drugs Law

Listing patent information in the Orange Book is a matter of judgment, but that judgment call is about to get a bit more scrutiny.

Related Keywords

United States , ,Drug Administration ,Trademark Office ,Orange Book ,Risk Evaluation ,Mitigation Strategy ,Federal Trade ,Listening Session ,That Policy Statement ,Policy Statement ,Commission Act ,Hatch Waxman Act ,Advisory Opinions ,Press Release ,First Circuit ,Purple Book ,Representative Annie Kuster ,Senators Maggie ,Mike Braun ,Patent Integrity ,United States Patent ,Mondaq ,To List Or Not That Is The Question X2013 Ftc Signals Potential For Greater Scrutiny Of Patent Information Submissions Fda ,Food ,Drugs ,Healthcare ,Life Sciences ,Food And Drugs Law ,Intellectual Property ,Patent ,